Phase 1 Myeloma Clinical Trials
177 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 177 trials
Recruiting
Phase 1
Personalized Autologous Transplant for Multiple Myeloma
Multiple Myeloma
Emory University90 enrolled2 locationsNCT04483206
Recruiting
Phase 1Phase 2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Plasma Cell Myeloma Refractory
Sanofi258 enrolled26 locationsNCT04643002
Recruiting
Phase 1
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Multiple MyelomaPlasma Cell Myeloma
Robert Flavell, MD, PhD20 enrolled1 locationNCT05892393
Recruiting
Phase 1
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
Newly Diagnosed Multiple Myeloma (NDMM)Multiple Myloma
The First Affiliated Hospital of Soochow University18 enrolled1 locationNCT07652138
Recruiting
Phase 1
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Multiple Myeloma
Pfizer87 enrolled43 locationsNCT06215118
Recruiting
Phase 1
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
University Health Network, Toronto20 enrolled1 locationNCT07456605
Recruiting
Phase 1
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
Myeloma
M.D. Anderson Cancer Center30 enrolled1 locationNCT05055063
Recruiting
Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory
Washington University School of Medicine52 enrolled1 locationNCT07200089
Recruiting
Phase 1
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Hoffmann-La Roche20 enrolled5 locationsNCT06934044
Recruiting
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Multiple Myeloma
Washington University School of Medicine20 enrolled1 locationNCT07200102
Recruiting
Phase 1Phase 2
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 1
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Multiple MyelomaMyelomaMyeloma, Multiple
K36 Therapeutics, Inc.165 enrolled22 locationsNCT05651932
Recruiting
Phase 1
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
AbbVie210 enrolled45 locationsNCT05650632
Recruiting
Phase 1
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Multiple MyelomaHematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.33 enrolled1 locationNCT07255898
Recruiting
Phase 1
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Multiple Myeloma
Shanghai Hengrui Pharmaceutical Co., Ltd.99 enrolled1 locationNCT07490613
Recruiting
Phase 1
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
Multiple Myeloma
Christopher Strouse10 enrolled1 locationNCT07581704
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Relapsed or Refractory Multiple Myeloma
Genentech, Inc.120 enrolled14 locationsNCT05927571
Recruiting
Phase 1Phase 2
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Multiple Myeloma
AstraZeneca226 enrolled40 locationsNCT06106945